Caladrius Biosciences Stock Price - CLBS

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Caladrius Biosciences Inc CLBS NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.07 -3.0% 2.26 2.39 2.17 2.23 2.33 18:00:20
Bid Price Ask Price Spread Spread % News
2.11 2.82 0.71 25.18% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
103 4,866 $ 2.27 $ 11,038 15,905 2.02 - 5.44
Last Trade Time Type Quantity Stock Price Currency
16:00:00 75 $ 2.26 USD

Caladrius Biosciences Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 23.51M 10.40M $ -16.17M -1.66 - 2.33M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 77.60%

more financials information »

Caladrius Biosciences News

Loading Messages....

Latest CLBS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CLBS Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week2.222.492.122.27849k0.041.80%
1 Month2.572.812.022.328316k-0.31-12.06%
3 Months2.973.082.022.507916k-0.71-23.91%
6 Months3.
1 Year4.575.442.023.435031k-2.31-50.55%
3 Years4.2211.652.025.642069k-1.96-46.45%
5 Years2323.52.029.3302119k-20.74-90.17%

Caladrius Biosciences Description

Caladrius Biosciences Inc is a therapeutics development biopharmaceutical company. It is engaged in the development of products that have the potential to restore the health of people with chronic illnesses. The company' product candidates include three developmental treatments for cardiovascular diseases; CLBS12 for the treatment of critical limb ischemia (CLI); CLBS14-CMD for the treatment of coronary microvascular dysfunction (CMD); CLBS14-NORDA for no-option refractory disabling angina (NORDA); and one autoimmune product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of Type 1 diabetes.

Your Recent History
Caladrius ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.